Loading clinical trials...
Loading clinical trials...
A Retrospective Chart Review of Real-world Treatment Outcomes in Patients With Locally Advanced Unresectable or Metastatic Urothelial Cancer Based on HER2 Expression
Conditions
Locations
23
United States
Mayo Clinic
Phoenix, Arizona, United States
University of California Irvine
Orange, California, United States
Stanford Cancer Institute - School of Medicine
Palo Alto, California, United States
University of California San Francisco
San Francisco, California, United States
University of California Los Angeles
Santa Monica, California, United States
University of Colorado Hospital
Aurora, Colorado, United States
Start Date
June 29, 2023
Primary Completion Date
June 18, 2025
Completion Date
June 18, 2025
Last Updated
July 20, 2025
NCT06857175
NCT04693377
NCT04895709
NCT06948552
NCT07061964
NCT05987241
Lead Sponsor
Seagen, a wholly owned subsidiary of Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions